FibroBiologics, Inc. Stock Issued During Period, Value, Other
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- FibroBiologics, Inc. stock issued during period, value, other for the quarter ending 2023-06-30 was $2.12M.
- FibroBiologics, Inc. stock issued during period, value, other for the quarter ending 2023-03-31 was $4.29M.
- FibroBiologics, Inc. stock issued during period, value, other for fiscal 2023 was $6.40M.
| Period end | Stock Issued During Period, Value, Other 3 month | Stock Issued During Period, Value, Other 12 month |
|---|---|---|
| 2023-12-31 | $6.40M 10-K · filed 2025-03-31 | |
| 2023-06-30 | $2.12M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $4.29M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 |